Australians with ADHD struggling amid critical medication shortage
The US Drug Enforcement Administration (DEA) has rejected a plea from Australian doctors to increase the supply of a critical ADHD medication, leaving patients struggling to find the treatment they need.
The drug, lisdexamfetamine dimesylate (LDX), is the only ADHD medication available in Australia from a single manufacturer, Takeda. However, Takeda has been experiencing manufacturing delays, leading to a severe shortage of the drug.
As a result, many Australians with ADHD have been forced to reduce their dosage or switch to alternative medications that may not be as effective. Some patients have even been unable to fill their prescriptions at all.
The shortage has had a significant impact on the lives of those affected. Many patients have reported experiencing increased symptoms of ADHD, such as difficulty concentrating, impulsivity, and hyperactivity. Some have also had to take time off work or school due to their symptoms.
In response to the shortage, the Australian Government has announced that it will be importing a limited supply of LDX from overseas. However, this is only a temporary measure, and it is unclear when the shortage will be fully resolved.
In the meantime, Australians with ADHD are being urged to speak to their doctor about alternative treatment options. There are a number of other medications that can be used to treat ADHD, and your doctor can help you find the best option for you.
Comments